

Manufacturers and Exporters of Bulk Drugs

12–6–214/A–1, Hyderabad Road, RAICHUR - 584 135, Karnataka, India.

Phone: +91-8532 - 238704, Fax: +91 - 8532 - 238876

E-Mail: info@vbshilpa.com Web: http://www.vbshilpa.com

CIN No. 185110KA1987PLC008739

MATERIAL SAFET1Y DATA SHEET OF THALIDOMIDE

1. IDENTIFICATION OF THE SUBSTANCE AND OF THE COMPANY

Substance name

THALIDOMIDE

Grade

USP

Company name

SHILPA MEDICARE LIMITED,

Street address

12-6-214/A-1, Hyderabad Road

City, state, zip, country

RAICHUR, KARNATAKA, 584 135, INDIA

Technical phone

++91-8532-236494

Emergency phone

++91-8532-235006

Fax

++91-8532-238876

2. COMPOSITION/INFORMATION ON INGREDIENT

CAS#

50-35-1

Formula

 $C_{13}H_{10}N_2O_4$

Chemical Names

2-(2,6-dioxo-3-piperidyl)isoindole-1,3-dione,

1H-Isoindole-1,3 (2H)-done, 2-(2,6-dioxo-3-piperidinyl)-,(+/-)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione,

distaval, softenon, talimol, 2-phthalimidoglutarimide, nibrol,

RTECS Number

TI43750000

Chemical Family

Glutamic acid derivative

Therapeutic Category

Immunomodulator; sedative-hypnotic

3. HAZARDS IDENTIFICATION

Usual Adult Dose:

the Usual oral adult dose of thalidomide is up to 400 mg a day

Adverse Effects:

Adverse effect may including tingling, buring, numbness, or pain in

extremities; muscle weakness; dizziness; drowsiness; constipation; diarrhea; nausea; stomach pain; dry mouth; dry skin; headache; increased appetite; mood changes; swelling of legs; and seizures. Possible allergic reaction to

material if inhaled, ingested or in contact with skin.

Over Dose Effects:

Over dose effects include lowered blood pressure, fever and sedation.

Acute:

Possible eye, skin, gastrointestinal and/or respiratory tract irritation.

Page 1 of 6



Manufacturers and Exporters of Bulk Drugs

12–6–214/A–1, Hyderabad Road, RAICHUR - 584 135, Karnataka, India.

Phone: +91-8532 - 238704, Fax: +91 - 8532 - 238876

E-Mail: info@vbshilpa.com Web: http://www.vbshilpa.com

CIN No. 185110KA1987PLC008739

MATERIAL SAFET1Y <u>DATA SHEET</u> OF THAL<u>IDOMIDE</u>

Chronic: Possible hypresensitization, decreased white blood cell count, and nerve

damage.

Inhalation: May cause Irritation. Remove to fresh air. Significant inhalation can cause

systematic effect.

Eye: May cause Irritation. Avoid contact. Flush with copious quantities of water for

at least 15 minutes. Seek medical attention.

Skin: May cause Irritation. Avoid contact. Flush with copious quantities of

soap and water at least 15 minutes. This material can be absorbed

through the skin.

Ingestion: May cause Irritation and toxicity. Avoid ingestion. Flush out mouth

with water. This material is slowly absorbed from the gastrointestinal

tract.

Medical Conditions

Aggravated by Exposure: Hypersensitivity to material, active alcoholism, Neutrogena, peripheral

neuropathy, and epilepsy or other factors predisposing to seizures.

Cross sensitivity: n/f

Pregnancy Comments: Therapeutic use of thalidomide by pregnant women has resulted in

severe fetal abnormalities including limb deformaties, ear and eye abnormalities, and congenital heart defects. Fetal and newborn death has also occurred. A single small dose early in pregnancy may cause these adverse effects. Males receiving thalidomide therapy are advised to use barrier contraception during sexual contact with women of

childbearing potential.

Pregnancy Category: X

4. FIRST AID MEASURES

General: Remove from exposure. Remove contaminated clothing. Persons

developing serious hypersensitivity (anaphylactic) reaction must receive immediate medical attention. If person is not breathing give artificial respiration. If breathing is difficult give oxygen.

Obtained medical attention.

Overdose treatment: Overdose treatment is symptomatic and supportive and may

include the following

Page 2 of 6

Innovating for affordable healthcare

Manufacturers and Exporters of Bulk Drugs

12–6–214/A–1, Hyderabad Road, RAICHUR - 584 135, Karnataka, India.

Phone: +91-8532 - 238704, Fax: +91 - 8532 - 238876

E-Mail: info@vbshilpa.com Web: http://www.vbshilpa.com

CIN No. 185110KA1987PLC008739

MATERIAL SAFET1Y DATA SHEET OF THALIDOMIDE

- 1. Do NOT Induce vomiting
- 2. Consider gastric lavage within 1 hour of ingestion of a very large amount.
- 3. Administer charcoal slurry.
- 4. Treat hypotension with infusion of isotonic fluid. Place patient in trendelenburg position. If hypotension persists, administer dopamine or nor epinephrine.
- 5. Monitor patient for central nervous system depression and peripheral neuropathies.
- 6. Because a single dose of thalidomide may cause severe birth defects, any female of childbearing potential exposed to thalidomide should obtain a pregnancy test. [Poisindex 2003]

In any case seek medical advice and call the nearest poison center.

5. FIRE FIGHTING MEASURES

Extinguishing media:

Water spray. Carbon dioxide, dry chemical powder or appropriate foam.

Fire fighting:

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes. Emits toxic fumes under fire conditions. Combustible.

6. ACCIDENTAL RELEASE MEASURES

Procedures of personal precautions:

Wear approved respirator, rubber gloves, chemical safety goggles.

Methods for cleaning up:

Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pick up is complete.

7. HANDLING, STORAGE AND SPILL

Handling:

Avoid all contact and inhalation of dust, mists and/or vapors associated with the material. Wash thoroughly after handling.

Page 3 of 6



Manufacturers and Exporters of Bulk Drugs

12-6-214/A-1, Hyderabad Road. RAICHUR - 584 135, Karnataka, India.

Phone: +91-8532 - 238704. Fax: +91 - 8532 - 238876

E-Mail: info@vbshilpa.com Web: http://www.vbshilpa.com

CIN No. L85110KA1987PLC008739

MATERIAL SAFET1Y DATA SHEET OF THALIDOMIDE

The material should be handled with care only by specially trained people avoiding all exposure and contamination. Pregnant women should avoid handling this substance.

Storage:

Preserve in tight container, protected from light, and store at room temperature.

Spill Response:

Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.

8. EXPOSURE CONTROLS/PERSONEL PROTECTION

Respiratory Protection:

Use a NIOSH approved respirator, if it is determined to be necessary by an industrial hygiene survey involving air monitoring. In the event that a respirator is not required, an approved dust mask should be used.

Ventilation:

Recommended

Gloves:

Rubber

Reye Protection:

Safety Goggles

Protection Clothing: Protect exposed skin

Engineering controls:

Mechanical exhaust required.

9. PHYSICAL AND CHEMICALS PROPERTIES

Molecular weight

258.23

Appearance

White to off-white powder

Solubility

Very soluble in dimethylformamide, in dioxane, and in pyridine; sparingly soluble in acetone, in butyl acetate, in ethanol, in ethyl acetate, in glacial acetic acid, in methanol and in water; practically insoluble in benzene, in chloroform,

and in ether.

Melting point

269 – 271° C

10. STABILITY AND REACTIVITY

Stability

Stable.

Conditions to Avoid:

Avoid exposure to light

Incompatibilities

strong oxidizing agents



Shitpa Innovating for affordable healthcare

Manufacturers and Exporters of Bulk Drugs

12–6–214/A–1, Hyderabad Road, RAICHUR - 584 135, Karnataka, India.

Phone: +91-8532 - 238704, Fax: +91 - 8532 - 238876

E-Mail: info@vbshilpa.com Web: http://www.vbshilpa.com

CIN No. L85110KA1987PLC008739

MATERIAL SAFET1Y DATA SHEET OF THALIDOMIDE

Hazardous decomposition products

NOx. Emits toxic fumes under fire conditions

Hazardous polymerization

Will not occur.

11. TOXICOLOGICAL INFORMATION

Target Organ (s)

: Central nervous system; immune system.

Listed as a Carcinogen

: NTP: No IARC: No OS

OSHA: No Other: No

. 1 1 1 1 . 1 1 0

Acute toxicity
Oral Rat

: LD50: 113 mg/kg

Oral Mouse

: LD50: 2 grams/kg

Irritation and corrosiveness

Irritates skin, eyes and respiratory tract.

Empirical data on effects on humans

Typical adverse effects include: gastrointestinal disturbances like nausea and vomiting. May cause late diarrhea. Animal tests have shown carcinogenic effects.

12. ECOLOGICAL INFORMATION

Not available.

13. DISPOSAL CONSIDERATIONS

The packaging and other material that has been contaminated by Thalidomide should be handled as hazardous waste in accordance with local and state laws and instructions.

14. TRANSPORT INFORMATION

Non-Hazardous for Transport

This substance is considered to be non-hazardous for transport.

Non-Hazardous for Air Transport

Non-hazardous for air transport

15. REGULATORY INFORMATION

Letter code of the warning symbol and indications of danger for the preparation:

Xn

Harmful

R-phrase(s)

R22

Harmful if swallowed.

R46

May cause heritable genetic damage.





Manufacturers and Exporters of Bulk Drugs

12–6–214/A–1, Hyderabad Road, RAICHUR - 584 135, Karnataka, India.

Phone: +91-8532 - 238704, Fax: +91 - 8532 - 238876

E-Mail: info@vbshilpa.com Web: http://www.vbshilpa.com

CIN No. L85110KA1987PLC008739

MATERIAL SAFET1Y DATA SHEET OF THALIDOMIDE

R61 May cause harm to unborn child.
R68 Possible risks of irreversible effects.

S-phrase(s)

S22 Do not breathe dust.

S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.

S45 In case of accident or if you feel unwell seek medical advice immediately.

Use only in well-ventilated areas.

S53 Avoid exposure-obtain special instructions before use.

Drug License No. KTK/25/256/89

Keep container in a well-ventilated place, protected from light. Keep away from sources of ignition. No smoking. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. In case of accident or if you feel unwell, seek medical advice immediately.

16. OTHER INFORMATION

DISCLAIMER

For manufacturing use only.

WARRANTY

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Shilpa Medicare Limited shall not be held liable for any damage resulting from handling or from contact with the above product.

